By THE ASSOCIATED PRESSSEPT. 20, 2016
Stocks on Wall Street inched higher on Tuesday in another cautious day of trading as investors kept an eye on the Federal Reserve and Japan’s central bank. Health care and household goods companies led the way, while energy companies slipped.Major market indexes were higher all day, but returned most of those gains at the close of trading. They rose just enough to cancel out Monday’s small losses.The Dow Jones industrial average gained 9.79 points, or 0.1 percent, to 18,129.96. The Standard & Poor’s 500-stock index added 0.64 points to 2,139.76. The Nasdaq composite picked up 6.33 points, or 0.1 percent, to 5,241.35.Drug companies helped health care stocks make some modest gains. Gilead Sciences gained $2.79, or 3.5 percent, to $81.78 after the drug maker completed a $5 billion debt offering. Gilead said it might use the cash to make a deal. Brian Abrahams, a Jefferies & Company analyst, said he thought the company was getting close to at least one acquisition. Separately, Merck rose 61 cents, or 1 percent, to $61.94.AdvertisementExxon Mobil fell on reports that it was being investigated by securities regulators. Exxon Mobil fell 1.5 percent, to $82.54 after Dow Jones reported that the Securities and Exchange Commission was investigating Exxon’s accounting practices and other issues.AdvertisementBond yields slipped and the dollar was little changed as investors waited decisions from the Fed and the Bank of Japan, which both started two-day meetings on Tuesday. The yield on the 10-year Treasury note fell to 1.69 percent from 1.71 percent.
            Position of the Dow Jones industrial average at 1-minute intervals on Tuesday.        18,24018,20018,160Previous close18,120.1718,12010 a.m.Noon2 p.m.4 p.m.SEPT. 20, 2016
While investors did not expect an increase in United States interest rates, the Japanese central bank was expected to take new steps to bolster the nation’s ailing economy. That could include an increase in its stimulus program or a further cut in the deposit rate as a way to encourage banks to lend money.The Ascena Retail Group, the parent of Ann Taylor, Lane Bryant and Dress Barn, dropped to a six-year low after the company reported weak quarterly results and gave a forecast that fell short of investor expectations. Its shares lost $2.43, or 29.9 percent, to $5.69.Allergan, the maker of Botox, announced yet another acquisition as it agreed to buy Tobira Therapeutics. Tobira is studying drugs that treat symptoms of nonalcoholic steatohepatitis, a disease that causes inflammation that can lead to cirrhosis, cancer and liver failure.Please verify you're not a robot by clicking the box.Invalid email address. Please re-enter.You must select a newsletter to subscribe to.View all New York Times newsletters.Tobira shares, which closed at $4.74 on Monday, surged to $38.91. Allergan fell $6.62, or 2.7 percent, to $238.67.The hotel chains Marriott and Starwood climbed after regulators in China approved the $14.41 billion deal that would bring them together to create the world’s largest hotel chain. Marriott, which is buying Starwood, said it expected to complete the deal on Friday. Marriott added $1.60, or 2.3 percent, to $69.94. Starwood rose $1.81, or 2.4 percent, to $76.90.The dollar rose to 101.74 yen from 101.81 yen. The euro slipped to $1.1157 from $1.1177.Benchmark crude picked up 14 cents, to $43.44 a barrel in New York. Brent crude, used to price international oils, slipped 7 cents, to $45.88 a barrel in London.Gold gained 40 cents, to $1,318.20 an ounce. Silver lost 1 cent, to $19.28 an ounce. Copper added 1 cent, to $2.17 a pound.The CAC in France 40 slipped 0.1 percent, while the German DAX rose 0.2 percent. In Britain, the FTSE 100 index was 0.3 percent higher. The benchmark Nikkei 225 in Tokyo closed down 0.2 percent. The Hang Seng in Hong Kong dipped 0.1 percent.A version of this article appears in print on September 21, 2016, on Page B5 of the New York edition with the headline: Small Gains Mostly Erased in Cautious Trading.  Order Reprints| Today's Paper|Subscribe

We’re interested in your feedback on this page. Tell us what you think.